Patent Opposition Database

Hide annotations

Related patent application (please put in national patent application/publication number or PCT application/publication number): AR112121A1
Who filed: CILFA
Country: Argentina
Opposition type: Pre-Grant
Opposition status: Under Examination
Date: 17-12-2019
Patent type: Combination

Click within the document, or manually enter the page number below

CILFA opposition, dapagliflozin-empagliflozin-insulin, (AR112015A1)

Countries: Argentina Date: 2019
CILFA opposition, cariprazine, (AR112137A1)

Countries: Argentina Date: 2019
CILFA opposition, buprenorphine, (AR110468A1)

Countries: Argentina Date: 2019
CILFA opposition, oprozomib, (AR110374A1)

Countries: Argentina Date: 2019
CILFA opposition, ibrutinib, (AR107391)

Countries: Argentina Date: 2019
CILFA opposition, LAS191954, (AR0100620A1)

Countries: Argentina Date: 2019
CILFA opposition, amino acids, (AR110548A1)

Countries: Argentina Date: 2019
CILFA opposition, trelagliptin, (AR109064A2)

Countries: Argentina Date: 2019
CILFA opposition, omega-3 polyunsaturated acids, (AR110450A1)

Countries: Argentina Date: 2019
CILFA opposition, brigatinib, (AR111169A1)

Countries: Argentina Date: 2019

Cilfa Opposition, Botulinum Toxin A, (Ar112121 A1)